$heff's $tation of $tocks & $olid DD

[$heff]

ACAD..$1.90..62% owned by institutions and only 34m shares in the float. The company has cash and this is a strong catalyst with a high unmet need. Still under 100M in market cap at current price. This price will not stay at under $2 for very long because the catalyst will draw closer. I personally like the risk/reward here. Because ACAD has previously failed and have worked with the FDA on the 020 trial they have worked diligently to avoid the pitfalls of prior unsuccessful trials. The benefit has come with the 9 item scale instead of the 20 item scale which the FDA agreed with. The chance of a successful trial in the 020 is very high!